vTv’s azeliragon study for Alzheimer’s disease and type 2 diabetes has support but some scepticism remains

The posthoc analyses from the STEADFAST study suggest that azeliragon may potentially be effective for the treatment of patients with mild AD and diabetes. Credit: Shutterstock.